Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) – HC Wainwright lifted their Q4 2023 EPS estimates for Gain Therapeutics in a research report issued to clients and investors on Monday, May 15th. HC Wainwright analyst B. Pachaiyappan now anticipates that the company will earn ($0.28) per share for the quarter, up from their previous estimate […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 59,800 shares, a decline of 7.1% from the April 15th total of 64,400 shares. Based on an average daily volume of 79,300 shares, the days-to-cover ratio is […]
CM Management LLC trimmed its holdings in Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) by 12.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 110,000 shares of the company’s stock after selling 15,000 shares during the quarter. CM Management LLC’s holdings in […]
Gain Therapeutics (NASDAQ:GANX – Get Rating) and Flora Growth (NASDAQ:FLGC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Valuation & Earnings This table compares Gain Therapeutics and […]